ERBB2 and cancer: Inetetamab, a product developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., is the result of refining the process of expressing the recombinant humanized anti-HER2 monoclonal antibody and was built upon prior foreign research endeavors.[26] Like trastuzumab, inetetamab acts on the extracellular part of the HER2 receptor, blocking the activation of intracellular tyrosine kinases and blocking the activation of human epidermal growth factor to HER2 by attaching itself to HER2, thus blocking the growth of cancer cells.